- Tilray Brands’ (TLRY) medical cannabis division, Tilray Medical, has expanded its European footprint across the Czech Republic
- The new partnership with Cansativa Group broadens Tilray Medical’s distribution of EU-GMP certified medical cannabis products across pharmacies and hospitals to support medical cannabis patient care
- Tilray Medical offers a portfolio of medical cannabis products in more than 20 countries that patients may access by consulting their healthcare practitioner
- Tilray Stock (TSX:TLRY) opened trading at C$2.49
Tilray Brands’ (TLRY) medical cannabis division, Tilray Medical, has expanded its European footprint across the Czech Republic.
Through a new export and distribution partnership with Cansativa Group, the new partnership broadens Tilray Medical’s distribution of EU-GMP certified medical cannabis products across pharmacies and hospitals to support medical cannabis patient care.
“Our Tilray Medical team remains dedicated to patient advocacy across our international markets by providing quality medicinal cannabis for commercial, compassionate access, and research purposes,” said the company’s Chief Strategy Officer and Head of International, Denise Faltischek.
Tilray Medical is one of the leading providers of EU-GMP certified medicinal cannabis in the world and offers a comprehensive portfolio of medical cannabis products in more than 20 countries that patients may access by consulting their healthcare practitioner.
Tilray Brands is a cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America.